NasdaqCM - Nasdaq Real Time Price USD

TC Biopharm (Holdings) Plc (TCBP)

1.5800

+0.0100

(+0.64%)

As of 3:19 PM EDT. Market Open.

TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging NK (natural killer) cells in treating both solid tumors and other indications.

PR Newswire 19 days ago

TCBP
+0.64%
TCBPW
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000.

PR Newswire 21 days ago

TCBP
+0.64%
TCBPW
TCBP Adjourns General Meeting Until a Later Date

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has adjourned its General Meeting of the Company to a later date.

PR Newswire last month

TCBP
+0.64%
TCBPW
TCBP Announces Exercise of Series D Warrants For Cash

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that an institutional investor has exercised cash only warrants represented 623,750 American Depository Shares (ADS) at an exercise price of $2.02.

PR Newswire last month

TCBP
+0.64%
TCBPW
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer, Bryan Kobel was again featured on a live interview on "The Big Biz Show," an Emmy Award-winning nationally syndicated TV and radio show.

PR Newswire last month

TCBP
+0.64%
TCBPW
/C O R R E C T I O N -- TC BioPharm/

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 4:30 p.m. ET.

PR Newswire last month

TCBP
+0.64%
TCBPW
TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the MHRA has officially accepted its proposed amendment to the Company's clinical trial authorisation (CTA). The amendment allows for an increase in dosing size of TCB008 (unmodified expanded gamma delta T cell Lymphocytes) to 12x10^7-23x10^7 gamma delta t-cells.

PR Newswire last month

TCBP
+0.64%
TCBPW
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured "Expert Speakers" at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.

PR Newswire 2 months ago

TCBP
+0.64%
TCBPW
TCBP Provides Shareholder Update and Highlights Upcoming Milestones

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a shareholder update with a projected outlook for the current year.

PR Newswire 2 months ago

TCBP
+0.64%
TCBPW
TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that its Chief Executive Officer, Bryan Kobel, was featured in live interview with the "Big Biz Show," an Emmy Award-winning nationally syndicated TV and radio show.

PR Newswire 2 months ago

TCBP
+0.64%
TCBPW
TC BioPharm to Present at the Sequire Investor Summit

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its participation at the upcoming Sequire Investor Summit 2024 scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.

PR Newswire 3 months ago

TCBP
+0.64%
TCBPW
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that on January 2, 2024, the Company received a written notice from The Nasdaq Stock Market ("Nasdaq"). The notice informed TC BioPharm that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capit

PR Newswire 3 months ago

TCBP
+0.64%
TCBPW
TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that the Company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway.

PR Newswire 3 months ago

TCBP
+0.64%
TCBPW
TC BioPharm Announces Closing of $3.5 Million Public Offering

TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the closing of its previously announced public offering of 1,750,000 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series E warrants (the "Series E Warrants") to purchase up to 1,750,000 of its ADSs at a public offering price of $2.00 per A

PR Newswire 3 months ago

TCBP
+0.64%
TCBPW
TC BioPharm Announces Pricing of $3.5 Million Public Offering

TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of a public offering of 1,750,000 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series E warrants (the "Series E Warrants") to purchase up to 1,750,000 of its ADSs at a public offering price of $2.00 per ADS (or pre-funded warra

PR Newswire 4 months ago

TCBP
+0.64%
TCBPW
TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the creation of a new Commercial Development Division, which will be headed by Dr. Lauren Bor, PhD.

PR Newswire 4 months ago

TCBP
+0.64%
TCBPW
TC BioPharm Announces Plan to Implement ADS Ratio Change

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that it will change its ratio of its American Depositary Shares ("ADSs") to ordinary shares from one (1) ADS representing one (1) ordinary share to one ADS representing twenty (20) ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on or about December 1

PR Newswire 4 months ago

TCBP
+0.64%
TCBPW
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug

The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.

Zacks 4 months ago

TCBP
+0.64%
TRDA

CTMX
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA provides clearance on the Company's investigational new drug (IND) application for a Phase 1B study in relapse/refractory Acute Myeloid Leukemia (AML).

PR Newswire 4 months ago

TCBP
+0.64%
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announces today that the Company has successfully completed its Safety Cohort and received positive review from the Data Safety Monitoring Board (DSMB).

PR Newswire 5 months ago

TCBP
+0.64%

Performance Overview

Return	TCBP	MSCI WORLD
YTD	-50.16%	+4.84%
1-Year	-99.46%	+17.69%
3-Year	--	+9.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TC Biopharm (Holdings) Plc (TCBP)

TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies

TCBP Increasing Treatment Capacity with Expanded Manufacturing Process

TCBP Adjourns General Meeting Until a Later Date

TCBP Announces Exercise of Series D Warrants For Cash

Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated "The Big Biz Show"

/C O R R E C T I O N -- TC BioPharm/

TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

TCBP Provides Shareholder Update and Highlights Upcoming Milestones

TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'

TC BioPharm to Present at the Sequire Investor Summit

TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement

TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies

TC BioPharm Announces Closing of $3.5 Million Public Offering

TC BioPharm Announces Pricing of $3.5 Million Public Offering

TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D

TC BioPharm Announces Plan to Implement ADS Ratio Change

TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug

TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia

TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results

Performance Overview